IPP Bureau
Lilly expands affordable access to diabetes & obesity medicines under new medicare programme
By IPP Bureau - March 10, 2026
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
Mumbai doctors perform India’s first robotic surgery to fix rare uterine defect in 23 year old
By IPP Bureau - March 10, 2026
Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy
Avio Smart teams up with Huwel Lifesciences to roll out next-gen molecular diagnostics in India
By IPP Bureau - March 10, 2026
Huwel’s diagnostic solutions leverage open RT-PCR system
FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
By IPP Bureau - March 10, 2026
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer
By IPP Bureau - March 10, 2026
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
AbbVie reports promising early results for novel obesity therapy ABBV-295
By IPP Bureau - March 10, 2026
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
By IPP Bureau - March 10, 2026
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Sumitomo Pharma bags world-first go-ahead for iPS cell therapy to treat Parkinson’s disease
By IPP Bureau - March 10, 2026
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer
By IPP Bureau - March 10, 2026
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
EU unveils draft guidance to fast-track clinical trials during public health emergencies
By IPP Bureau - March 09, 2026
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
By IPP Bureau - March 09, 2026
DiaMedica said it plans to launch the trial later in 2026
SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients
By IPP Bureau - March 09, 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
Lupin receives two observations from USFDA for Ankleshwar facility
By IPP Bureau - March 09, 2026
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
Roche’s Gazyva shows breakthrough results in Lupus phase III trial
By IPP Bureau - March 07, 2026
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
